Urethroplasty — Cost, Top Hospitals & Success Rates | MyMedicPlus

Urethroplasty is the gold-standard surgical reconstruction of a narrowed or obstructed urethra — the tube that carries urine from the bladder to the outside of the body. It is the definitive treatment for urethral stricture disease, a condition in which scar tissue progressively narrows the urethral lumen, causing obstructed urinary flow, recurrent urinary tract infections, and in severe cases, urinary retention and renal impairment.

Unlike endoscopic procedures such as direct-vision internal urethrotomy (DVIU) or urethral dilation, which cut or stretch the scar without removing it, urethroplasty physically excises or bypasses the diseased segment and reconstructs the urethra with healthy tissue. Large multi-centre studies published in European Urology and the Journal of Urology consistently show 5-year success rates of 85–97% for urethroplasty, compared with 20–30% success for repeated endoscopic procedures.

The procedure is performed by a reconstructive urologist or urological surgeon and is tailored to the location, length, and aetiology of the stricture. Major surgical categories include excision and primary anastomosis (EPA) for short strictures and substitution urethroplasty — most commonly using a buccal mucosal graft (BMG) harvested from the inner cheek — for longer or more complex strictures.

Urethroplasty is performed under general or spinal anaesthesia. Most patients are discharged within 1–2 days and require a urethral catheter for 3–4 weeks while the repair heals. Long-term outcomes are excellent, with the majority of patients achieving durable, unobstructed voiding without further interventions.

Urethroplasty is indicated for urethral stricture disease arising from a variety of causes. The specific technique chosen depends on the length, site, and underlying aetiology of the stricture.

• Urethral stricture disease (anterior urethra): Narrowing of the penile, bulbar, or panurethral urethra due to inflammation, infection, instrumentation, or trauma. The bulbar urethra is the most common site, accounting for over 50% of all strictures in adults.
• Posterior urethral distraction defects (PUDD): Complete disruption of the posterior urethra following pelvic fracture urethral injury (PFUI), resulting in a fibrous gap between the bladder neck and the proximal bulbar urethra.
• Lichen sclerosus (LS-related stricture): A chronic inflammatory dermatosis that causes progressive, obliterative stricturing, often involving the fossa navicularis and extending into the bulbar urethra. Requires non-genital skin grafts (BMG) as LS-affected tissue is unsuitable for reconstruction.
• Failed hypospadias repair: Recurrent stricture or fistula following childhood hypospadias correction requiring complex multi-stage reconstruction.
• Post-prostatectomy anastomotic stenosis: Narrowing at the bladder neck–urethral anastomosis following radical prostatectomy for prostate cancer.
• Radiation-induced stricture: Progressive fibrosis and obliteration of the urethra following radiotherapy for pelvic malignancy, representing the most surgically challenging subtype.

Urethroplasty may also be indicated for recurrent stricture after two or more failed endoscopic procedures, or for primary treatment when stricture length exceeds 1.5–2 cm, where endoscopic options have very low durable success rates.

Urethroplasty is suitable for most patients with symptomatic urethral stricture disease who have failed conservative management or in whom definitive repair is preferred. Pre-operative evaluation is thorough and guides surgical planning.

Diagnostic Work-Up

• Retrograde urethrogram (RGU): Fluoroscopic contrast study defining the length, location, and calibre of the stricture — the cornerstone of pre-operative planning.
• Voiding cystourethrogram (VCUG): Assesses the proximal urethra and bladder neck simultaneously, essential for posterior strictures.
• Uroflowmetry and post-void residual: Quantifies the degree of outflow obstruction and bladder emptying.
• Flexible urethrocystoscopy: Direct visualisation of the stricture and assessment of urethral mucosal health.
• Ultrasound of spongiofibrosis: Perineal ultrasound identifies the depth of spongiofibrosis, aiding technique selection.
• MRI (selected cases): Used for complex posterior strictures to define the gap length and pelvic anatomy.

Patient Fitness Factors

Candidates must be medically optimised for surgery. Factors considered include cardiac and pulmonary fitness for anaesthesia, glycaemic control in diabetic patients (elevated HbA1c increases wound-healing risk), absence of active urinary tract infection, cessation of anticoagulant therapy, and smoking cessation (ideally 6 weeks pre-operatively) to optimise tissue perfusion. Patients on chronic immunosuppression require specialist co-management. There is no absolute upper age limit; many centres report excellent outcomes in patients over 70 years.

Urethroplasty encompasses a spectrum of reconstructive techniques. Technique selection is based on stricture length, location, aetiology, degree of spongiofibrosis, and surgeon expertise.

1. Excision and Primary Anastomosis (EPA)

For bulbar urethral strictures shorter than 1.5–2 cm, the scarred segment is completely excised and the healthy urethral ends are spatulated and anastomosed tension-free. This eliminates all diseased tissue and achieves the highest reported success rates of 90–97% at 5 years. Longer strictures are unsuitable due to tension on the anastomosis and risk of chordee.

2. Buccal Mucosal Graft (BMG) Urethroplasty

BMG, harvested from the inner cheek (buccal mucosa), is the most widely used graft material for substitution urethroplasty. Its properties — hairlessness, resistance to wet environments, excellent take due to high lamina propria vascularity — make it ideal for urethral reconstruction. It can be placed as a dorsal onlay (Barbagli technique: graft placed on the dorsal urethra, secured against the tunica albuginea of the corpora), ventral onlay, or dorsal inlay (Asopa technique: graft inlaid through a ventral urethrotomy). The choice depends on the degree of spongiofibrosis and surgeon preference. BMG success rates are 80–90% at 5 years for strictures 2–10 cm in length.

3. Skin Flap Urethroplasty

Penile or perineal skin flaps (fasciocutaneous flaps based on the dartos fascia) can be used when buccal mucosa is unavailable or insufficient. The Orandi flap and McAninch circular fasciocutaneous flap are established options. These are technically demanding but provide well-vascularised tissue.

4. Perineal Urethrostomy (Johanson Procedure)

For patients with extensive panurethral strictures or multiple failed prior urethroplasties, a permanent perineal urethrostomy (permanent urethral opening in the perineum) may be the most functional option, offering reliable drainage without complex reconstruction.

5. Two-Stage Urethroplasty

Used for complex strictures with severe spongiofibrosis, failed prior grafts, or lichen sclerosus. Stage 1 involves marsupialization of the urethral plate with graft inlay. Stage 2 (6–12 months later) involves tubularisation. Success rates are comparable to single-stage approaches for complex cases.

6. Posterior Urethroplasty for PFUI

The perineal posterior urethroplasty (Turner-Warwick approach) re-establishes urethral continuity after pelvic fracture urethral injury. The fibrotic gap is excised and a tension-free EPA is performed via a perineal approach with or without pubectomy. Success rates exceed 90% in experienced centres.

Urethroplasty offers durable, definitive relief from urethral stricture disease that endoscopic procedures cannot consistently achieve. The evidence base spans multiple prospective cohort studies and meta-analyses.

• High long-term success rates: EPA achieves 90–97% patent urethra at 5 years; BMG urethroplasty achieves 80–90% at 5 years — substantially superior to repeat DVIU (20–30% durable success).
• Significant symptom improvement: Patients experience marked improvement in peak urinary flow rate (Qmax), International Prostate Symptom Score (IPSS), and quality-of-life scores. Mean Qmax typically improves from under 10 mL/s pre-operatively to over 20 mL/s post-operatively.
• Elimination of recurrent procedures: Unlike endoscopic management — which often requires repeated dilation or urethrotomies every 6–12 months — successful urethroplasty is typically a one-time intervention.
• Preservation of sexual function: Modern bulbar urethroplasty techniques, particularly perineum-sparing EPA and dorsal BMG, have low rates of erectile dysfunction (5–10% reported in prospective studies), significantly lower than previously feared.
• Prevention of complications: Definitive repair prevents progressive renal damage from obstructive uropathy, recurrent urinary tract infections, epididymo-orchitis, bladder calculi, and prostatitis associated with chronic untreated stricture.
• Cost-effectiveness: Health economic analyses demonstrate that urethroplasty, despite higher upfront cost, is more cost-effective than repeated endoscopic procedures over a 5–10 year horizon.

Urethroplasty is a safe procedure with a favourable risk profile, but patients should be counselled on potential complications categorised by timing.

Intra-Operative Risks

• Bleeding requiring transfusion (rare, <1%)
• Rectal injury during perineal dissection (rare, <0.5%)
• Anaesthetic complications

Early Post-Operative Complications

• Urinary tract infection: Common with indwelling catheter; managed with prophylactic or therapeutic antibiotics.
• Wound infection or haematoma: Occurs in 3–8% of cases; most resolve with conservative management.
• Catheter-related discomfort: Managed with antispasmodics and adequate analgesia during the 3–4 week catheterisation period.
• Urinary leak or fistula: Rare (<2%); typically managed conservatively with prolonged catheterisation.

Late Complications

• Stricture recurrence: Occurs in 5–15% depending on technique and case complexity; detected by symptom recurrence and confirmed by uroflowmetry or urethrogram.
• Erectile dysfunction: Reported in 5–10% of bulbar urethroplasties; more common after posterior urethroplasty for PFUI (up to 30%), often attributed to pre-existing nerve injury from the original trauma rather than surgery.
• Ejaculatory dysfunction: Retrograde ejaculation or altered ejaculation in a minority of patients, more common after posterior procedures.
• Chordee (penile curvature): Uncommon after properly performed bulbar EPA; more frequent after anterior urethral repair.
• Donor site complications (BMG): Temporary numbness, restricted mouth opening, and minor scarring of the cheek are reported in 5–15% of patients; serious complications are rare.

All patients undergo post-operative surveillance with uroflowmetry at 3 months, 6 months, and 12 months, then annually. Retrograde urethrogram is reserved for symptomatic recurrence or declining flow rates.

Post-operative recovery from urethroplasty follows a predictable course. Structured follow-up is essential to confirm surgical success and detect early recurrence.

Immediate Post-Operative Period (Days 1–4)

Most patients are discharged within 24–48 hours with a urethral catheter in situ. Perineal wounds are closed primarily and covered with a light dressing. Pain is managed with oral analgesics (paracetamol, NSAIDs, and short-course opioids if needed). Patients are encouraged to mobilise gently and maintain adequate fluid intake to keep the catheter draining freely.

Catheter Phase (Weeks 1–4)

The urethral catheter remains in place for 3–4 weeks (longer for complex reconstructions). A retrograde urethrogram or cystogram is performed before catheter removal to confirm watertight anastomosis. Patients receive written instructions on catheter care, signs of infection (fever, cloudy urine, pericatheter leakage), and emergency contacts.

Return to Activity (Weeks 4–6)

After catheter removal, most patients void immediately with improved flow. Mild urgency and frequency are common in the first 2–4 weeks as the bladder adapts. Strenuous activity, cycling, and sexual intercourse should be avoided for 4–6 weeks. Perineal discomfort typically resolves within 3–4 weeks. Driving can usually resume after 2–3 weeks.

Long-Term Surveillance

Surveillance uroflowmetry at 3, 6, and 12 months, then annually for 5 years. A sustained Qmax above 15 mL/s with no symptomatic recurrence defines success. Patients are advised to report dysuria, weak stream, or straining promptly. Stricture recurrence detected early (before obliteration) can be managed by single DVIU, preserving options for revision urethroplasty if needed.

The cost of urethroplasty varies considerably by country, hospital type, surgical complexity, and choice of technique. Understanding the components of cost helps patients plan and compare international options.

Cost Components

• Surgeon and anaesthetist fees
• Operating theatre and equipment charges
• Hospital admission (1–2 nights)
• Pre-operative diagnostic investigations (RGU, VCUG, uroflowmetry, blood tests)
• Post-operative catheter and wound care
• Follow-up consultations and surveillance uroflowmetry

Estimated Cost Ranges by Country

• United States: USD 15,000–35,000 (significantly higher at academic centres for complex cases)
• United Kingdom: GBP 6,000–12,000 (private sector)
• India: USD 2,500–6,000 at JCI/NABH-accredited centres
• Thailand: USD 4,000–9,000
• Turkey: USD 3,500–8,000
• Mexico: USD 4,000–9,000

Patients travelling internationally for urethroplasty should factor in two visits — one pre-operative consultation and the surgery trip — or arrange for pre-operative investigations to be transmitted electronically for remote surgical planning. Insurance coverage varies; urethroplasty is considered reconstructive (not cosmetic) and is covered by most health insurance plans in countries with universal coverage.

Several less invasive options exist for urethral stricture management, though none match the long-term durability of urethroplasty in most patients. The choice depends on stricture characteristics, patient fitness, and patient preference.

• Urethral dilation: Gradual mechanical stretching of the stricture using bougies or balloon dilators. Provides temporary symptom relief but does not address the underlying scar tissue. Success rates fall below 30% at 2 years with repeated procedures. Often used as a temporising measure in elderly or high-operative-risk patients.
• Direct-vision internal urethrotomy (DVIU): Endoscopic cold-knife or laser incision of the stricture. First-time DVIU for a single, short (<1.5 cm) bulbar stricture achieves approximately 50% success at 1 year, but repeated procedures show diminishing returns (20–30% success). Widely available, minimally invasive, and performed as day surgery.
• Urethral stent (Urolume): A permanent metallic endoluminal stent deployed across the stricture. Largely abandoned due to high rates of stent migration, tissue ingrowth, chronic pain, and difficulty with subsequent surgical revision. Not recommended in current guidelines except in very selected cases.
• Intralesional mitomycin C (MMC): Injection of an anti-fibrotic agent at the time of DVIU to reduce stricture recurrence. Evidence is mixed; some studies show modest improvement in recurrence-free intervals, but results are inconsistent across randomised trials.
• Clean intermittent self-catheterisation (CISC): Regular self-catheterisation to maintain urethral patency without surgical intervention. A valid long-term management strategy for patients unsuitable for surgery, though dependent on patient compliance and dexterity.
• Suprapubic cystostomy: Surgical creation of a suprapubic drainage tube bypassing the urethra entirely. Used as temporary urinary diversion prior to definitive repair, or as permanent palliation in patients unfit for reconstruction.